These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 33049260)

  • 1. Adapting ADME and Pharmacokinetic Analysis to the Next Generation of Therapeutic Modalities.
    Hochman JH
    J Pharm Sci; 2021 Jan; 110(1):35-41. PubMed ID: 33049260
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetic and pharmacodynamic considerations for the next generation protein therapeutics.
    Shah DK
    J Pharmacokinet Pharmacodyn; 2015 Oct; 42(5):553-71. PubMed ID: 26373957
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mathematical Models to Characterize the Absorption, Distribution, Metabolism, and Excretion of Protein Therapeutics.
    Liu S; Shah DK
    Drug Metab Dispos; 2022 Jun; 50(6):867-878. PubMed ID: 35197311
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics and ADME characterizations of antibody-drug conjugates.
    Lin K; Tibbitts J; Shen BQ
    Methods Mol Biol; 2013; 1045():117-31. PubMed ID: 23913144
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evidence-based absorption, distribution, metabolism, excretion (ADME) and its interplay with alternative toxicity methods.
    Tsaioun K; Blaauboer BJ; Hartung T
    ALTEX; 2016; 33(4):343-358. PubMed ID: 27806179
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics in Drug Discovery: An Exposure-Centred Approach to Optimising and Predicting Drug Efficacy and Safety.
    Reichel A; Lienau P
    Handb Exp Pharmacol; 2016; 232():235-60. PubMed ID: 26330260
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ADME Considerations and Bioanalytical Strategies for Pharmacokinetic Assessments of Antibody-Drug Conjugates.
    Mou S; Huang Y; Rosenbaum AI
    Antibodies (Basel); 2018 Nov; 7(4):. PubMed ID: 31544891
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transitioning from Basic toward Systems Pharmacodynamic Models: Lessons from Corticosteroids.
    Ayyar VS; Jusko WJ
    Pharmacol Rev; 2020 Apr; 72(2):414-438. PubMed ID: 32123034
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tools for predicting the PK/PD of therapeutic proteins.
    Diao L; Meibohm B
    Expert Opin Drug Metab Toxicol; 2015 Jul; 11(7):1115-25. PubMed ID: 25936400
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Estimating human ADME properties, pharmacokinetic parameters and likely clinical dose in drug discovery.
    Lucas AJ; Sproston JL; Barton P; Riley RJ
    Expert Opin Drug Discov; 2019 Dec; 14(12):1313-1327. PubMed ID: 31538500
    [No Abstract]   [Full Text] [Related]  

  • 11. Pharmacokinetic and Drug Metabolism Properties of Novel Therapeutic Modalities.
    Rock BM; Foti RS
    Drug Metab Dispos; 2019 Oct; 47(10):1097-1099. PubMed ID: 31399505
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In-silico ADME models: a general assessment of their utility in drug discovery applications.
    Gleeson MP; Hersey A; Hannongbua S
    Curr Top Med Chem; 2011; 11(4):358-81. PubMed ID: 21320065
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modeling in translational drug research.
    Danhof M; de Lange EC; Della Pasqua OE; Ploeger BA; Voskuyl RA
    Trends Pharmacol Sci; 2008 Apr; 29(4):186-91. PubMed ID: 18353445
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of preclinical in vitro and in vivo ADME properties and prediction of human PK using a physiologically based pharmacokinetic model for YQA-14, a new dopamine D3 receptor antagonist candidate for treatment of drug addiction.
    Liu F; Zhuang X; Yang C; Li Z; Xiong S; Zhang Z; Li J; Lu C; Zhang Z
    Biopharm Drug Dispos; 2014 Jul; 35(5):296-307. PubMed ID: 24647883
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictive Pediatric Modeling and Simulation Using Ontogeny Information.
    Ince I; Solodenko J; Frechen S; Dallmann A; Niederalt C; Schlender J; Burghaus R; Lippert J; Willmann S
    J Clin Pharmacol; 2019 Sep; 59 Suppl 1():S95-S103. PubMed ID: 31502689
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biomeasures and mechanistic modeling highlight PK/PD risks for a monoclonal antibody targeting Fn14 in kidney disease.
    Chen X; Farrokhi V; Singh P; Ocana MF; Patel J; Lin LL; Neubert H; Brodfuehrer J
    MAbs; 2018 Jan; 10(1):62-70. PubMed ID: 29190188
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development and application of physiologically based pharmacokinetic-modeling tools to support drug discovery.
    Lüpfert C; Reichel A
    Chem Biodivers; 2005 Nov; 2(11):1462-86. PubMed ID: 17191947
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A tiered approach to pharmacokinetic studies.
    Wilson AG; Frantz SW; Keifer LC
    Environ Health Perspect; 1994 Dec; 102 Suppl 11(Suppl 11):5-11. PubMed ID: 7737041
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of ADME characteristics in drug discovery and their in silico evaluation: in silico screening of chemicals for their metabolic stability.
    Gombar VK; Silver IS; Zhao Z
    Curr Top Med Chem; 2003; 3(11):1205-25. PubMed ID: 12769701
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacological considerations for predicting PK/PD at the site of action for therapeutic proteins.
    Wang W; Zhou H
    Drug Discov Today Technol; 2016; 21-22():35-39. PubMed ID: 27978986
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.